anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Traction

Slide type collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 10,471
Current window 5,701-5,730
Pages 350
Rows per page 30
Slide type: Tractionclear collectionreset all
18 30 60

Slide type

5,701-5,730 of 10,471

filter-aware
19
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
29
The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
31
The slide uses bar charts to compare IMX-110 performance against standard drugs like Trabectedin and a 4-drug combination.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
Includes waterfall charts and longitudinal patient response plots; highlights PFS (progression-free survival) and line of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
Includes two sets of charts: tumor volume line graphs and survival curves. References specific study methodology in footnotes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
TPD stands for Targeted Protein Degradation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
25
Data presented for All HS Patients (N=12) and Moderate to Severe (N=10) subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
38
The slide presents clinical trial data for a drug candidate, comparing PK profiles across four dose levels (DL1-DL4).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
40
The slide uses a split-layout to contrast clinical data findings with the strategic clinical development plan.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit